ACADIA Pharmaceuticals (ACAD) R&D Day 2025 summary

Pipeline Overview and Program Updates

• Pipeline includes nine disclosed programs, with eight expected in the clinic by year-end and multiple undisclosed projects; seven Phase 2/3 studies are anticipated to start by end of 2026.

• Five key assets (ACP-204, ACP-211, ACP-711, ACP-271, ACP-101) target high unmet needs in neurology and rare diseases, with risk-adjusted peak sales potential of $2.5B and up to $12B if all succeed.

• Commercial brands NUPLAZID and DAYBUE are expected to generate over $1B in combined revenue in 2025, with projections for peak sales of $1.5B–$2B.

• Expansion into adjacent rare disease categories and rare epilepsies is underway, leveraging internal capabilities and external partnerships.

• Early-stage pipeline includes programs for rare epilepsies (e.g., SYNGAP1-related disorders) and other undisclosed neurological targets.

Clinical Trial Data and Development Milestones

• Seven Phase 2 or 3 studies are set to launch by 2026, with five major readouts expected by 2027.

• ACP-204 (for Alzheimer's and Lewy body dementia psychosis) is in Phase 2/3, with topline data expected by mid-2026; designed to improve efficacy and safety over pimavanserin.

• ACP-211 (oral, deuterated R-norketamine) is entering Phase 2 for major depressive disorder in late 2025, aiming for ketamine-like efficacy with minimal sedation/dissociation.

• ACP-711 (GABA alpha-3 modulator) is in Phase 1 in elderly, with Phase 2 in essential tremor planned for 2026.

• ACP-271 (GPR88 agonist) is advancing for tardive dyskinesia and Huntington's disease, with first-in-human studies by year-end and preclinical data showing durable efficacy.

• ACP-101 (intranasal carbetocin) Phase 3 in Prader-Willi syndrome is fully enrolled, with data expected in early Q4 2025 and potential approval in Q3 2026.

• DAYBUE (trofinetide) is approved for Rett syndrome in the US and Canada, with EMA approval anticipated in Q1 2026 and a Japan study starting in Q3 2024.

R&D Strategy and Innovation Priorities

• R&D strategy is anchored in precision medicine, data innovation, globalization, and patient empowerment.

• Focus on risk diversification, objective endpoints, and biomarker-driven development to de-risk clinical programs.

• Pipeline advancement is driven by disciplined decision-making, with molecules required to earn their place and stay based on rigorous criteria.

• Commitment to building a sustainable, balanced pipeline by stage and risk profile, leveraging strong financial flexibility.

• Geographic expansion of talent hubs in the U.S. and Switzerland to attract top-tier talent.